Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels

British Journal of Pharmacology
E J HideJ R Vane

Abstract

1. This study examined whether pretreatment of rabbits with infusions of prostaglandin E1 (PGE1) or prostaglandin E0 (PGE0) (which were terminated prior to the onset of ischaemia) reduce myocardial infarct size arising from coronary artery occlusion (60 min) and reperfusion (120 min). In addition, we investigated whether the observed cardioprotective effects of these two prostaglandins were due to the activation of ATP-sensitive potassium (KATP) channels. 2. In the anaesthetized rabbit, infarct size (expressed as a percentage of the area at risk) after 60 min of coronary artery occlusion followed by 2 h of reperfusion was 59 +/- 4% (n = 10). PGE1 or PGE0 treatment (1.0 micrograms kg-1 min-1), administered as 1 h pretreatments (0.05 ml min-1, i.v.), significantly reduced infarct size to 44 +/- 6% (n = 6) or 42 +/- 1% (n = 6), respectively. PGE1 or PGE0 pretreatment resulted in a significant reduction in mean arterial blood pressure, which returned to baseline within 15 min of discontinuation of the infusion (i.e. prior to LAL ligation). 3. The reduction in infarct size afforded by PGE1 was abolished by pretreatment of rabbits with the KATP channel blockers, glibenclamide (60 +/- 4%; n = 8) or 5-hydroxydecanoate (58 +/- 6%; n = 6...Continue Reading

References

Jan 1, 1992·Journal of Cardiovascular Pharmacology·G J GrossG M Pieper
Oct 1, 1991·Circulation Research·J R McCulloughG J Grover
Apr 1, 1990·Circulation Research·R J SchottW Schaper
Aug 1, 1990·Circulation·G C LiB R Lucchesi
Mar 1, 1973·Cardiovascular Research·I HuttonT D Lawrie
Oct 1, 1984·International Journal of Cardiology·N A FloresD J Sheridan
Mar 1, 1981·Basic Research in Cardiology·D BallerG Hellige

❮ Previous
Next ❯

Citations

Sep 29, 2007·Pflügers Archiv : European journal of physiology·Li-Fang HuJin-Song Bian
Aug 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·K ShinmuraR Bolli
Jun 16, 2009·The Journal of Surgical Research·Ulf Abdel-RahmanFriedhelm Beyersdorf
Aug 11, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Sapna AggarwalAmteshwar Singh Jaggi
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Mahmoud Abu-AmaraBrian R Davidson
Sep 10, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·K ZacharowskiC Thiemermann
Dec 20, 2007·Journal of Cardiovascular Pharmacology·Satoru EguchiNobuyoshi Nakajo
Dec 18, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Ken ShinmuraRoberto Bolli
Nov 21, 2008·Anesthesia and Analgesia·Nina C WeberBenedikt Preckel
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Brigitta M PeskarBernhard A Peskar
Oct 22, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Ken ShinmuraRoberto Bolli
Oct 12, 1999·The American Journal of Physiology·T YamamotoM Yoshimura
Jun 29, 2002·Anesthesia and Analgesia·Connail R McCrory, Sten G E Lindahl

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.